



The Secretary
Listing Department,
BSE Limited,
1st Floor, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400001
Scrip Code: 540975

The Manager,
Listing Department,
The National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Scrip Symbol: ASTERDM

Dear Sir/Madam,

Sub: Press Release on unaudited financial results for the quarter ended June 30, 2022

With reference to the captioned subject, please find enclosed press release in relation to the unaudited financial results of the Company for the quarter ended June 30, 2022.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank you

For Aster DM Healthcare Limited

Hemish Purushottam

Company Secretary and Compliance Officer



Aster DM Healthcare Q1 FY23 Results

Consolidated revenue from operations up 12% YoY to Rs. 2,662 Crs.

Adjusted EBITDA* up 11 % YoY to Rs. 312 Crs. PAT up 34% YoY to 80 Crs.

India revenue from operations up 18% YoY to Rs. 651 Crs., EBITDA up 18% YoY to Rs. 84 Crs. and PAT (Post NCI) from a loss of Rs. 1 Cr. to a profit of Rs. 19 Crs., YoY

Kochi, August 11, 2022: Aster DM Healthcare, one of the largest private healthcare service providers in GCC and in India, today announced its financial results for the quarter ended June 30, 2022.

KEY HIGHLIGHTS OF THE QUARTER

- Operational Revenue increased by 12% Y-o-Y to Rs. 2,662 Crs. compared to Rs. 2,372 Crs.
- EBITDA (excluding other income) increased by 4 % Y-o-Y to Rs. 292 Crs. as compared to Rs. 281 Crs in Q1 FY 22. Excluding losses due to new hospitals, EBITDA stands at Rs. 312 Cr., a growth of 11% Y-o-Y.
- PAT (Pre- Non-Controlling Interest) increased by 34% to Rs. 80 Crs. compared to Rs. 60 Crs. in Q1 FY 22. Adjusting for losses due to new hospitals and one-time Other Income, PAT (Pre- Non-Controlling Interest) grew 49% to Rs. 89 Crs.

Commenting on the performance for Q1 FY23, Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare, said:

"We have started Q1 on a positive note with revenue growth of 12% on a consolidated basis. Revenue in the GCC increased 10% over last year while strong growth momentum in India continued, with revenues growing 18% over Q1 FY 22. Adjusting for contribution from Covid testing last year, GCC revenues grew 18%. In India revenues grew 26% when adjusting for Covid related vaccinations. This clearly indicates growth of business activity across both geographies.

During Q1, we started operations management of the 140-bed Aster Mother Hospital in Areekode in Kerala, kick starting our planned brown field, low capex initiatives which give a much better ROI and improve our efficiencies. We are looking at more such opportunities in various parts of India.

^{*} Adjusted EBITDA excludes losses arising from new hospitals



We have submitted plans for the proposed integrated advanced healthcare facility at Trivandrum, capital of Kerala named as Aster Capital Hospital. The hospital is planned to be a 550-bed facility with the first phase having a capacity of 350 beds expected to be operational by FY 26.

Aster Labs entered four other States: Maharashtra, Tamil Nadu, Andhra Pradesh, and Telangana. As of 30th June 2022, there were 2 reference labs, 15 satellite labs and 109 patient experience centers.

We expanded Aster Pharmacy branded retail stores in India, operated by Alfaone Retail Pharmacies Private Limited or ARPPL, to 176 pharmacies as of 30th June 2022. As part of its service proposition, Aster Pharmacy in India plans to launch its e-commerce operations, in the second half of FY 23."

Commenting on Aster's New Business Initiatives, Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare, said:

"We have two of our new hospitals ready for operation- Aster Sharjah, which has 101 beds the soft launch of which happened during Q1 and Aster Royal at Oman with 145 beds. We are excited to get them operational in Quarter 2 of this Year as we expand our footprint in GCC.

Our new initiatives in Digital expansion continue along the planned lines. We did successful launch of our Digital App in GCC which shall be made available in India soon."

About Aster DM Healthcare

Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 29 hospitals, 121 clinics, 421* pharmacies, 17 labs and 109 patient experience centers in seven countries, including India. We have over 27,200 plus dedicated staff including 3,441 doctors and 7,901 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well." We reach out to all economic segments in the GCC states through our differentiated healthcare services across the "Aster", "Medcare" and "Access" brands.

For more information about us, please visit www.asterdmhealthcare.com or contact:

Saurabh Paliwal

Head of Investor Relations

Aster DM Healthcare

Tel: +91 95383 80801

saurabh.paliwal@asterdmhealthcare.com

Lavanya Mandal

Head of PR and Internal Communication

Aster DM Healthcare

Tel: +971 52 8126577

<u>lavanya.mandal@asterdmhealthcare.com</u>





* Including 176 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.

DISCLAIMER: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.